Inmaculada Bernal-Bernal

Inmaculada Bernal-Bernal

Auto-generated profile, based on publicly available information

Inmaculada Bernal-Bernal

Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SJSilvia Jesús
Silvia Jesús
IHIsmael Huertas
Ismael Huertas
IBInmaculada Bernal-Bernal
Inmaculada Bernal-Bernal
MBMarta Bonilla-Toribio
Marta Bonilla-Toribio
MCMaría Teresa Cáceres-Redondo
María Teresa Cáceres-Redondo
PMPablo Mir
Pablo Mir
The presence of mutations in glucocerebrosidase (GBA) gene is a known factor increasing the risk of developing Parkinson’s disease (PD). Mutations carriers have earlier disease onset and are more likely to develop neuropsychiatric symptoms than other sporadic PD cases. These symptoms have primarily been observed in Parkinson’s patients carrying the most common pathogenic mutations L444P and N370S. However, recent findings suggest that other variants across the gene may have a different impact on the phenotype as well as on the disease progression. We aimed to explore the influence of variants across GBA gene on the clinical features and treatment related complications in PD. In this study, we screened the GBA gene in a cohort of 532 well-characterised PD patients and 542 controls from southern Spain. The potential pathogeniticy of the identified variants was assessed using in-silico analysis and subsequently classified as benign or deleterious. As a result, we observed a higher frequency of GBA variants in PD patients (12.2% vs. 7.9% in controls, p = 0.021), earlier mean age at disease onset in GBA variant carriers (50.6 vs. 56.6 years; p = 0.013), as well as more prevalent motor and non-motor symptoms in patients carrying deleterious variants. In addition, we found that dopaminergic motor complications are influenced by both benign and deleterious variants. Our results highlight the fact that the impact on the phenotype highly depends on the potential pathogenicity of the carried variants. Therefore, the course of motor and non-motor symptoms as well as treatment-related motor complications could be influenced by GBA variants.

11 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IHIsmael Huertas
Ismael Huertas
SJSilvia Jesús
Silvia Jesús
FGFrancisco Javier García-Gómez
Francisco Javier García-Gómez
JLJosé Antonio Lojo
José Antonio Lojo
IBInmaculada Bernal-Bernal
Inmaculada Bernal-Bernal
PMPablo Mir
Pablo Mir
The dual syndrome hypothesis for cognitive impairment in Parkinson's disease (PD) establishes a dichotomy between a frontrostriatal dopamine-mediated syndrome, which leads to executive deficits, and a posterior cortical syndrome, which leads to dementia. Certain genes have been linked to these syndromes although the exact contribution is still controversial. The study’s objective was to investigate the role of APOE, MAPT, COMT, SNCA and GBA genes in the dual syndromes. We genotyped APOE (rs429358 and rs7412), MAPT (rs9468), COMT (rs4680) and SNCA (rs356219) risk polymorphisms and sequenced GBA in a cohort of 298 PD patients. The degree of dopaminergic depletion was investigated with [123I]FP-CIT SPECTs and the presence of dementia was ascertained with a long-term review based on established criteria. The association between genetic and imaging parameters was studied with linear regression, and the relationship with dementia onset with Cox regression. We found that APOE2 allele (Pput = 0.002; Pcau = 0.01), the minor allele 'G' in SNCA polymorphism (Pput = 0.02; Pcau = 0.006) and GBA deleterious variants in (Pput = 0.01; Pcau = 0.001) had a detrimental effect on striatal [123I]FP-CIT uptake in PD. Conversely, Met/Met carriers in COMT polymorphism had increased caudate uptake (Pcau = 0.03). The development of dementia was influenced by APOE4 allele (HR = 1.90; P = 0.03) and GBA deleterious variants (HR = 2.44; P = 0.01). Finally, we observed no role of MAPT locus in any of the syndromes. As a conclusion, APOE2, SNCA, COMT and GBA influence frontostriatal dysfunction whereas APOE4 and GBA influence the development of dementia, suggesting a double-edged role of GBA. The dichotomy of the dual syndromes may be driven by a broad dichotomy in these genetic factors.

25 September 2014 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
PGPilar Gómez‐Garre
Pilar Gómez‐Garre
IHIsmael Huertas‐Fernández
Ismael Huertas‐Fernández
MCMaría Teresa Cáceres‐Redondo
María Teresa Cáceres‐Redondo
AAAraceli Alonso‐Canovas
Araceli Alonso‐Canovas
IBInmaculada Bernal‐Bernal
Inmaculada Bernal‐Bernal
PMPablo Mir
Pablo Mir

12 June 2015 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
IHIsmael Huertas‐Fernández
Ismael Huertas‐Fernández
PGPilar Gomez-Garre
Pilar Gomez-Garre
MMMarcos Madruga‐Garrido
Marcos Madruga‐Garrido
IBInmaculada Bernal‐Bernal
Inmaculada Bernal‐Bernal
MBMarta Bonilla‐Toribio
Marta Bonilla‐Toribio
PMPablo Mir
Pablo Mir

29 August 2012 in European Neurology
Verified
Journal Article
Closed access
PGPilar Gomez-Garre
Pilar Gomez-Garre
SJSilvia Jesús
Silvia Jesús
FCFátima Carrillo
Fátima Carrillo
MCMaria Teresa Cáceres-Redondo
Maria Teresa Cáceres-Redondo
IBInmaculada Bernal-Bernal
Inmaculada Bernal-Bernal
PMPablo Mir
Pablo Mir
Background: Impairment of the ubiquitin-proteasome system has been suggested to play an important role in the pathogenesis of Parkinson’s disease (PD). The 26S proteasome regulatory subunit 1 is encoded by the gene PSMC1 in humans. PSMC1 knockout mice showed a PD-like phenotype. Our aim was to analyze the association between variations in this gene and the susceptibility to develop PD. Methods: We included 283 PD patients (165 males and 118 females) with a mean age of 63.6 ± 11.2 years (mean age at onset 55.4 ± 12.7 years), and 316 unrelated control subjects (193 males and 123 females) with a mean age of 61.5 ± 12.3 years. Four polymorphisms, providing haplotype information of PSMC1, were genotyped using TaqMan assays. Moreover, in order to identify new variations, all exons of the PSMC1 gene and their exon-intron boundaries were analyzed using high-resolution melting analysis. Results: Minor allele frequencies in PD patients and control subjects were similar. The gene coding sequence analysis showed no variation associated with the disease either. Conclusions: Our results suggest that there is no association between variations or haplotypes in the PSMC1 gene and PD, indicating that this gene is probably not involved in the pathogenesis of PD.

30 May 2013 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
SJSilvia Jesús
Silvia Jesús
PGPilar Gomez-Garre
Pilar Gomez-Garre
FCFátima Carrillo
Fátima Carrillo
MCMaría T. Cáceres-Redondo
María T. Cáceres-Redondo
IHIsmael Huertas-Fernández
Ismael Huertas-Fernández
PMPablo Mir
Pablo Mir